Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CS 10BR05

Next Previous
X
Search
Drug Profile

CS 10BR05

Alternative Names: Bone marrow-derived mesenchymal stem cells; CS-10BR05

Latest Information Update: 28 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CORESTEM
  • Developer Corestemchemon
  • Class Mesenchymal stem cell therapies; Neuroprotectants
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple system atrophy

Most Recent Events

  • 28 Aug 2023 No recent reports of development identified for phase-I development in Multiple system atrophy in South Korea (Intra-arterial, Injection)
  • 20 Aug 2020 Safety efficacy and pharmacodynamic data from phase I trial in Multiple system atrophy released by Corestem and Yonsei University College of Medicine
  • 28 Aug 2018 Corestem initiates phase I trial for Multiple system atrophy I South Korea (intra-arterial, Injection) (NCT04495582)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top